Edgewise Therapeutics (EWTX) Projected to Post Earnings on Monday

Edgewise Therapeutics (NASDAQ:EWTX) will likely be issuing its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 6, 2026 at 9:30 AM ET.

Edgewise Therapeutics Stock Performance

EWTX opened at $29.31 on Monday. Edgewise Therapeutics has a one year low of $10.60 and a one year high of $31.29. The company has a market cap of $3.10 billion, a P/E ratio of -18.55 and a beta of 0.27. The business’s 50-day simple moving average is $26.91 and its 200-day simple moving average is $20.67.

Insider Activity

In other news, Director Badreddin Edris sold 115,471 shares of the company’s stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $29.44, for a total transaction of $3,399,466.24. Following the completion of the sale, the director owned 19,820 shares in the company, valued at $583,500.80. This represents a 85.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 23.20% of the company’s stock.

Hedge Funds Weigh In On Edgewise Therapeutics

Several institutional investors have recently bought and sold shares of EWTX. Orbimed Advisors LLC lifted its stake in shares of Edgewise Therapeutics by 3.3% in the 2nd quarter. Orbimed Advisors LLC now owns 15,518,492 shares of the company’s stock worth $203,447,000 after acquiring an additional 496,771 shares during the period. RA Capital Management L.P. increased its stake in shares of Edgewise Therapeutics by 5.3% during the third quarter. RA Capital Management L.P. now owns 10,428,437 shares of the company’s stock worth $169,149,000 after acquiring an additional 525,804 shares during the period. Paradigm Biocapital Advisors LP raised its holdings in Edgewise Therapeutics by 6.0% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 6,541,210 shares of the company’s stock worth $162,320,000 after purchasing an additional 371,079 shares in the last quarter. Siren L.L.C. lifted its position in Edgewise Therapeutics by 16.2% in the fourth quarter. Siren L.L.C. now owns 4,529,990 shares of the company’s stock valued at $112,412,000 after purchasing an additional 632,891 shares during the period. Finally, Morgan Stanley lifted its position in Edgewise Therapeutics by 234.7% in the fourth quarter. Morgan Stanley now owns 2,910,881 shares of the company’s stock valued at $72,234,000 after purchasing an additional 2,041,203 shares during the period.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Piper Sandler reissued an “overweight” rating on shares of Edgewise Therapeutics in a report on Monday, February 9th. Royal Bank Of Canada increased their target price on shares of Edgewise Therapeutics from $49.00 to $50.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Wall Street Zen upgraded shares of Edgewise Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, February 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Edgewise Therapeutics in a research note on Wednesday, January 21st. Finally, JPMorgan Chase & Co. raised their price objective on Edgewise Therapeutics from $33.00 to $34.00 and gave the stock an “overweight” rating in a report on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $36.67.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.